This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Voyager (VYGR) in Focus: Stock Moves 5.7% Higher
by Zacks Equity Research
Voyager (VYGR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Novartis (NVS) Gets CRL From the FDA for Cholesterol Drug
by Zacks Equity Research
Novartis (NVS) gets CRL from the FDA for its cholesterol drug, inclisiran, due to unresolved facility inspection-related conditions.
Atea Pharmaceuticals (AVIR) Jumps: Stock Rises 9.5%
by Zacks Equity Research
Atea Pharmaceuticals (AVIR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Anika Therapeutics (ANIK) Surges: Stock Moves 6.6% Higher
by Zacks Equity Research
Anika Therapeutics (ANIK) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
4 Healthcare Stocks to Take Care of in 2021 to Boost Portfolio
by Srijita Guha
Based on strong fundamentals, here we talk about four healthcare stocks to keep in your watchlist for 2021.
X4 Pharmaceuticals (XFOR) Surges: Stock Moves 6.9% Higher
by Zacks Equity Research
X4 Pharmaceuticals (XFOR) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Lumos Pharma (LUMO) in Focus: Stock Moves 8.3% Higher
by Zacks Equity Research
Lumos Pharma (LUMO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
NeuroBo Pharmaceuticals (NRBO) Surges: Stock Moves 5.2% Higher
by Zacks Equity Research
NeuroBo Pharmaceuticals (NRBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Buy 5 Top Stocks with Strong Earnings Beat Prospects
by Sanghamitra Saha
Invest in top-ranked stocks that are likely to beat earnings estimates in the upcoming releases.
Cellectis (CLLS) Jumps: Stock Rises 9%
by Zacks Equity Research
Cellectis (CLLS) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
Gilead's (GILD) CAR T Cell Therapy Tecartus Wins EC Nod
by Zacks Equity Research
Gilead (GILD) company, Kite, gets conditional marketing authorization for CAR T cell therapy, Tecartus.
Genprex (GNPX) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Genprex (GNPX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Athenex (ATNX) Gets FDA Approval for Skin Treatment Klisyri
by Zacks Equity Research
Athenex (ATNX) wins the FDA nod for Klisyri as a topical treatment of actinic keratosis on the face or scalp. The drug will be launched in the first quarter of 2021 in the United States.
Lilly (LLY) to Acquire Prevail Therapeutics for Gene Therapies
by Zacks Equity Research
Lilly (LLY) inks a deal to acquire Prevail Therapeutics for an upfront payment of $880 million, which will add gene therapy programs to its pipeline.
Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (RGEN) Outperforming Other Medical Stocks This Year?
Acceleron's (XLRN) PAH Candidate Gets Orphan Designation in EU
by Zacks Equity Research
Acceleron's (XLRN) investigational therapy sotatercept receives an Orphan designation in Europe for the treatment of patients with pulmonary arterial hypertension. Shares up.
Viatris (VTRS) to Cut Jobs as Part of Restructuring Initiative
by Zacks Equity Research
Viatris (VTRS) announces job cuts as part of additional details of its previously disclosed multi-year global restructuring initiative.
Alexion (ALXN) to Be Acquired by AstraZeneca for $39 Billion
by Zacks Equity Research
Alexion (ALXN) is set to be acquired by AstraZeneca for $39 billion or $175 per share. The acquisition is expected to close in the third quarter of 2021.
Gilead (GILD) to Buy MYR GmbH for EUR1.15 Billion in Cash
by Zacks Equity Research
Gilead (GILD) will purchase MYR GmbH for EUR1.15 billion and add HDV treatment Hepcludex to its portfolio.
Rocket Pharmaceuticals (RCKT) Surges on Encouraging Study Data
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) AAV-based gene therapy candidate demonstrates early evidence of clinical benefit and tolerability in patients with Danon disease, which affects the cardiac muscle.
scPharmaceuticals (SCPH) Plunges on Complete Response Letter
by Zacks Equity Research
scPharmaceuticals (SCPH) receives complete response letter from the FDA regarding an NDA for its pipeline candidate, Furoscix, as a potential treatment for congestion due to fluid overload in adult patients.
Why Is Repligen (RGEN) Down 6.7% Since Last Earnings Report?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioCryst (BCRX) Wins FDA Approval for HAE Drug Orladeyo
by Zacks Equity Research
BioCryst (BCRX) obtains FDA approval for berotralstat for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients.
Deere & Co, Chico's FAS, Aerpio Pharmaceuticals, TRACON Pharmaceuticals and Repligen Corp highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Deere & Co, Chico's FAS, Aerpio Pharmaceuticals, TRACON Pharmaceuticals and Repligen Corp highlighted as Zacks Bull and Bear of the Day
3 Biotech Stocks to Buy on First Vaccine Approval Optimism
by Zacks Equity Research
Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors. It will also help biotechs progress with their clinical studies without any disruption.